Abstract The gamma amino butyric acid (GABA) transporters GAT-1 and GAT-3 were localized by immunohistochemistry in hippocampi removed for the control of medically intractable temporal lobe epilepsy (TLE). The study aimed to determine the relationship of GABA transporter expression to known patterns of hippocampal hyperexcitability and extracellular GABA levels. GAT-1 was localized in axon terminals and small neuronal cell bodies, and in non-sclerotic hippocampi was strongly expressed throughout all regions of the hippocampal formation. In the epileptogenic hippocampus exhibiting Ammon's horn sclerosis, immunoreactivity was reduced in the sclerotic regions CA3 and CA1, and around the cell bodies of dentate granule cells, but was increased along granule cell dendrites. GAT-3 was weakly expressed, if at all, in non-sclerotic hippocampi, but more prominently expressed in sclerotic hippocampi. GAT-3 expression was confined to cells resembling protoplasmic astrocytes, which were located in regions of relative neuronal sparing such as the dentate gyrus and hilus of the sclerotic hippocampus. The reduction in GAT-1 around granule cells in the sclerotic hippocampus could explain the prolonged GABA responses in this region. The loss of GAT-1 (a marker of GABAergic terminals) would also suggest a reduced GABAergic input to the granule cells, thus facilitating hyperexcitability. The increased GAT-3 expression in astrocytes in regions of relative neuronal sparing in the sclerotic hippocampus may be related to the overall low levels of extracellular GABA observed in the sclerotic hippocampus and their increased excitability.
Introduction
Gamma amino butyric acid (GABA) is the major inhibitory neurotransmitter in the brain. A deficiency in GABA-mediated inhibition in epilepsy is hypothesized to produce neuronal hyperexcitability [3] . Temporal lobe epilepsy (TLE), one of the commonest forms of medically intractable epilepsy syndromes, is characterized by seizures that originate from the temporal lobe. An alteration in the balance between excitation and inhibition is thought to produce hyperexcitability in temporal lobe structures, especially the hippocampus. While high levels of extracellular glutamate [18] and an increase in glutamate receptors [5, 12] are reported in TLE hippocampi, the involvement of GABA in TLE is equivocal.
Some anatomical studies report that GABAergic neurons are lost [21, 29] while others report that they are preserved in the epileptogenic hippocampus [2] and that GABA receptors are maintained unchanged on surviving neurons [24] . Further, whereas some electrophysiological studies of human TLE hippocampi with mesial sclerosis report a small loss of GABA-mediated inhibition [23, 28, 30] , others have observed a prolonged GABA A -receptor mediated response in dentate granule cells of MTLE hippocampi [40] . The prolonged GABA A -receptor response is hypothesized to be due to impairment in the clearance of synaptically released GABA.
In vivo microdialysis of the hippocampi in patients with TLE show that shortly before the onset of seizures, the extracellular concentrations of glutamate are higher and those of GABA lower in the epileptogenic hippocampus compared to the non-epileptogenic hippocampus of the same patient [18] . The GABA concentrations increase in both hippocampi during and after the seizure, and there is a significantly higher concentration of GABA in the non-epileptogenic hippocampus after the seizure. Electrophysiological analysis of the GABA response reveal that the glutamate-induced calcium-independent release of GABA is significantly decreased in the epileptogenic hippocampus compared to the nonepileptogenic hippocampus [17] . It is hypothesized that the diminished glutamate-induced release of GABA in the epileptogenic hippocampus is caused by a reduction of GABA transporters [17] although no direct measurements of GABA transporters in the human hippocampus have been made.
The uptake of synaptically released GABA is mediated by a family of electrogenic, sodium-dependent transporters [6, 7, 26] . At least four distinct types of GABA specific transporter proteins have been characterized and cloned from animal and human brain tissue, and classified as GAT-1 to GAT-3 and BGT-1 [4, 25] . These GABA transporter subtypes are differentially distributed in the brain [11, 19, 22] . GAT-1, GAT-3, and BGT-1 are detected only in the brain, while GAT-2 is found in various tissues particularly in the arachnoid and ependymal tissue. GAT-1 is the most abundant transporter in the hippocampus, whereas GAT-3 is found at very low levels, if at all.
In the present study we evaluate by immunohistochemistry and immunoblots, the hypothesis that the relatively low levels of glutamate-induced extracellular GABA in the epileptogenic hippocampus is caused by a reduction in hippocampal GABA transporters, especially GAT-1 and GAT-3.
Materials and methods

Patients and tissue
The human hippocampal samples analyzed in this study were obtained through the Yale epilepsy surgery program. The hippocampi were surgically removed from patients with medically intractable TLE. Tissue used in these studies was obtained after informed consent and with approval of the institutional human investigations committee (HIC). The criteria for the selection of patients for surgery and the surgical method for en bloc resection of this tissue are described previously [37, 38] .
Hippocampi from 24 patients were collected for analysis. These hippocampi were categorized on the basis of immunohistochemical staining for neuropeptide Y (NPY), somatostatin (SOM), substance P (SP) and dynorphin (DYN), and cell counts [13] . Cell counts were made from hematoxylin and eosin stained sections as described in Kim et al. [27] . A complete description of the criteria for patient classification is given in de Lanerolle et al. [14] . Thus the hippocampi were divided into five groups. (1) Mesial temporal lobe epilepsy (MTLE, n=12) where the hippocampi had extensive neuronal loss and immunohistochemical evidence of reorganization of NPY, SOM, SP, and DYN immunoreactive elements in the dentate molecular layer [14] , (2) Hippocampi with mesial temporal sclerosis but without DYN immunoreactivity in the inner molecular layer (IML) of the dentate (MTLE/DYN -, n=2), (3) Hippocampi with sclerosis in the CA1 area only, with no reorganization of the dentate gyrus (CA1-only group, n=2), (4) Hippocampi with an extrahippocampal temporal lobe mass lesion (MaTLE, n=5). These hippocampi showed no sclerosis, (5) Hippocampi with no evidence of sclerosis or a mass lesion, were described previously [36] as paradoxical temporal lobe epilepsy (PTLE, n=3). In this paper groups 1-3 are described together as sclerotic hippocampi, whereas groups 4 and 5 are described as non-sclerotic hippocampi.
Immunohistochemistry
Hippocampal tissue blocks, approximately 0.5 cm thick, were fixed by immersion in a solution of 4% paraformaldehyde with 15% v/v picric acid (using a solution of saturated picric acid) in phosphate buffer, pH 7.4 (PB) for 3 h and then stored in PB. Fifty microns thick vibratome sections were used for immunocytochemistry with the avidin-biotin complex method as described previously [13] . Antibodies against GAT-1 were AB1570 (Chemicon, Tamecula, CA, USA) and Anti-GAT1, 584 (gift from N.C. Danbolt, Oslo, Norway), which were raised in rabbit and affinity purified. The antibodies were directed against the amino acid 584-599 in the rat sequence (GPEQP-QAGSSASKEAYI), which only differs by three amino acids in human (GPEHAQAGSSTSKEAYI). The antibody to GAT-3 (AB1574, Chemicon; and 7D4318, gift from N.C. Danbolt) was also made against its C-terminus (aa 607-677). The antibodies were used at dilutions of 1:2,000 for 48 h at 4°C. The diluted GAT1 and GAT3 antibodies were preadsorbed with GAT1 and GAT3 control peptides, respectively (#PP94 and PP96, Chemicon) for antibody specificity tests. The primary antibodies were omitted in tests of tissue specificity controls. These controls resulted in the blocking of staining. The specificity of some of the antibodies (anti GAT1 584 and anti-GAT3 7D4318) was also determined by immunoblotting with extracts of non-MTLE hippocampus (IH635) (Fig. 1) . Both antibodies produced immunoreactive bands around the expected molecular weights for GAT1 and GAT3. However, anti-GAT3 also gave a single narrow band with at 50 kDa. Substitution of the primary antibodies with normal serum completely abolished staining.
Electron microscopy was carried out on the immunostained tissue sections. After post-fixation with osmium tetroxide, the sections were stained en bloc in 1% uranyl acetate, dehydrated and embedded in epoxy resin (Durcapan, Fluka, AG, Buchs SG, Switzerland). Ultrathin sections were cut and examined with a transmission electron microscope (Joel EM300).
In this paper, immunostaining was not quantified as it is shown that the variability inherent in immunostaining from case to case makes quantification of immunoreactivity inaccurate [9, 10] . We have adopted a qualitative description of features that were clear and could be differentiated in all hippocampal specimens.
Western blot analysis
Sections containing all hippocampal subregions were cut from frozen PTLE and MTLE specimens. The tissue was homogenized in ten tissue volumes of SDS-solubilization buffer (1% SDS with 150 mM NaCl and 10 mM PB pH 7.4) with protease inhibitors 5 mM EDTA and 1 mM phenylmethylsulfonyl fluoride (PMSF), using a FastPrep Ò Instrument (Qbiogene Inc., Ca, USA), and the FastRNA Ò Pro Green Kit (Qbiogene Inc.). The homogenates were then incubated for 10 min on ice and centrifuged (1000·g, 10 min, 15°C). The supernatant solutions were stored at 80°C.
The protein concentration of the samples was determined using BCA Protein Assay Kit (Pierce, #23227). Bovine serum albumin (BSA) was used as standard and the determination was performed according to manufacturer's protocol. After protein determination, protein homogenates were diluted with SDS-sample buffer containing 2-mercaptoethanol and applied at a concentration of 2-14 lg protein per lane from each patient on precast polyacrylamide gels (Criterion, 10% Tris-HCl, BIORAD). The gels were run (200 V, 55 min) in Criterion TM Cell Electrophoresis Module, BIORAD. After SDS-PAGE the gels were electroblotted onto nitrocellulose (Western blotting, 100 V, 1 h) using the ECL methods with supersignal west Dura extended duration substrate (Pierce, #34075). Briefly, the blots were blocked (30 min) The blots were then exposed to X-ray film (Hyperfilm TM MP, Amersham Biosciences) and developed. The X-ray films were scanned and the intensity of the bands was calculated for GAT1 and GAT3 using ImageJ (ImageJ 1.29· Software, Wayne Rasband, National Institutes of Health, USA). The GAT1 and GAT3 antibodies both gave a single band on the blots, consistent with the expected molecular mass. Substitution of the primary antibodies with normal serum completely abolished the staining. The blots were assessed for differences between the MTLE and non-MTLE (PTLE) hippocampi using a two-tailed Mann-Whitney U-test (Statview Software).
Results
Clinical characteristics of patients
The demographic and clinical characteristics of the patients used in this study were similar to those in a larger sample reported previously [14] (Table 1) . Similar numbers of males and females were studied in each group, thus any differences observed are unlikely to be gender specific. The ages of the patients in each group were also similar (MTLE mean 33.25 years ±13.7 SD; MTLE/DYN-32.7±15.6; CA1 only group 34.5±26.1; MaTLE 32.6±16.4 and PTLE 38.6±11.8). The mean age to the first seizure in the sclerotic patients (MTLE 5±6, MTLE/DYN-1.96, CA1 only 3.6) was shorter than in the non-sclerotic MaTLE group (17.8±17), but similar to the PTLE (2.8). The duration of seizure history prior to surgery was longer in the sclerotic patients (mean 28.3, 27.0, 30.8) and non-sclerotic PTLE hippocampi (37.2) than in the non-sclerotic MaTLE (14.6±12.4). In both these features these patient groups resembled those in much larger samples reported previously [14] . Fig. 1 The specificity of the polyclonal GABA transporter antibodies as demonstrated by immunoblotting of electrophoretically separated proteins. Immunoblot of crude SDS extracts of non-MTLE human hippocampus (IH635) were subjected to SDS-PAGE (4, 8, and 14 lg protein/lane) and reacted with anti-GAT1 (anti-GAT1 (584) rabbit 68514, 6/21/98, 1 lg/ml, lanes 1-3), and anti-GAT3 (anti-GAT3, rabbit 7D4318, 6/21/98, 1 lg/ml, lanes 4-6) antibodies followed by peroxidase conjugated secondary antibodies (Anti-rabbit IgG peroxidase conjugate, Sigma, A-1949, diluted 1:40000). Both antibodies show a band around the expected molecular weight, but anti-GAT3 also shows a single narrow band with a molecular weight of 50 kDa. Substitution of the primary antibodies with normal serum completely abolished the staining (not shown). Molecular mass markers (kDa) are indicated All MTLE and MTLE/DYN-and CA1 group patients had significant (p<0.05) neuronal loss in area CA1 (typical of hippocampal sclerosis) compared to non-sclerotic patients (PTLE and MaTLE) ( Table 2, 3) . Both MTLE and MTLE/ DYN À -hippocampi also had significant loss of neurons in the dentate granule cell layer (Table 2 and Fig. 2 ) but as previously reported [14] , the CA1 only group had neuronal densities in the dentate gyrus that were similar to non-sclerotic PTLE and MaTLE hippocampi. Among the MaTLE and PTLE hippocampi in this study all, except one MaTLE case, were non-sclerotic. In this one MaTLE patient (IH428), which had hippocampal sclerosis, the ganglioglioma was in the amygdala and invaded the edge of the hippocampus. Such a pattern has been reported previously for hippocampus-invading mass lesions [20] . There was no difference between groups as regards the anti-epileptic drugs they were on at the time of surgery.
Localization of GAT-1
Light microscopically, GAT-1 immunoreactivity was found in fine, beaded, axon-like processes and small particulate elements. Electron microscopically, immunoreactivity was localized to axon terminals throughout the hippocampus (Fig. 3a , b, terminals in area CA2). This confirms that the transporter was localized presynaptically. A few small neuronal cell bodies were also immunoreactive for GAT-1 (Fig. 3c , cell body in area CA1 of MTLE). The immunoreactivity was associated with the rough endoplasmic reticulum (RER) in the cell body suggesting that the transporter may be synthesized in the cell body and translocated to the axon terminal.
The small size and morphology of the cell bodies resembled those of GABAergic neurons.
Non-sclerotic hippocampi-MaTLE and PTLE groups
The pattern of distribution of GAT1 in MaTLE and PTLE hippocampi was similar and these hippocampi are described together. The distribution of GAT-1 immunoreactivity was seen throughout the hippocampus, appearing, at low power magnification, as a diffuse pattern of labeling most prominently in the cell body layers such as the granular layer of the dentate (Fig. 4a ) and pyramidal layer of Ammon's horn and subiculum (Fig. 5a, g ). GAT-1 immmunoreactive puncta and fine axonal processes were found surrounding the soma of granule cells throughout the dentate granule cell layer (7/ 8 non-sclerotic cases compared to 0/12 MTLE cases, Figs. 4a and 5a ). Throughout the IML of the dentate gyrus, immunoreactivity for GAT-1 was found in very fine punctate particles (Figs. 4a and 5c ). However, at low magnification the IML appeared relatively lightly stained compared to the middle and outer molecular layers (Fig. 4a) . The latter regions were more intensely stained and the immunoreactive particles appeared to run along the perforant path fibers (not shown). The subgranular zone of the hilus appeared as a paler region compared to the inner hilar region (Fig. 4a) and also showed fine immunoreactive particles. Within the hilar region and in the pyramidal layer of CA3, CA2, and CA1, elongated processes were also heavily outlined by immunostained elements. This pattern of immunoreactivity is consistent with expression around the initial segments of axons of pyramidal cells [16] (Fig. 4d) . Immunoreactive fibers ran within the stratum oriens, forming a lightly stained network along the edge of the pyramidal layer (Fig. 5e ).
Occasional patches of fine immunoreactive axons were present in the alveus (Fig. 4c ) and the fibers appeared more prominently along the obliterated fissure close to the subicular region. Within the subiculum also GAT-1 immunoreactivity was consistent with expression around axon initial segments of layer 2 clusters of neurons, and was seen throughout the rest of the subiculum as fine punctate elements (Fig. 5g) .
Sclerotic hippocampi-MTLE, MTLE/DYN -, CA1 only groups
In the MTLE group, the overall distribution of GAT-1 immunoreactivity was similar to that of non-sclerotic hippocampi, but reflected the pattern of neuronal loss seen in the former; i.e. where neurons were lost, GAT-1 immunoreactivity was reduced as well. This was best Fig. 2 Photomicrographs of the dentate granule cell layer in a Nissl stained section from a a non-sclerotic (MaTLE) hippocampus (a). The granule cell layer is compact and thick, and separates a neuron rich subgranular region (below) from a relatively neuron-sparse molecular layer above. b A sclerotic (MTLE) hippocampus showing loss of granular neurons, which is extensive in some parts (left half) and dispersed in other areas (right half). Bar =20 lm CA3, CA2, CA1 respective areas of Ammon's horn, GC granule cell layer of dentate, IML inner molecular layer, M/OML middle/outer molecular layer, SUB subiculum. The number of plus signs are a qualitative index of staining intensity seen relative to area CA1, which had significant cell loss and thus was lightly stained up to the borders with CA2 and the subiculum, on either side, which were more darkly stained because of the greater density of neurons. However, there were a few specific changes seen in MTLE alone. In the granule cell layer the immunoreactive axons did not closely surround the granule cell soma; instead they appeared to extend perpendicularly to the granule cell layer passing through the granular cells into the IML (Figs. 4b and 5b ). Immunoreactive elements in the IML, instead of being scattered as in non-sclerotic hippocampi, were arranged along the apical dendrites of granule cells, giving an appearance of fine striations in the IML and obliterating the clear margins of this region seen in MaTLE-11/12 cases compared to 0/8 non-sclerotic cases (Figs. 4b and 5d ). In the granule cell layer, some surviving patches of granule cells appeared to have a heavy network of stained fibers that wrapped around them (Fig. 5b) . In the middle and outer molecular layer the staining intensity was still greater than the IML, and stained fibers ran along with the transversely oriented axons of the perforant path in the outer molecular layer. In the hilus, due to a reduction in the number of large neurons, there were fewer large neuronal dendrites encrusted with immunoreactive axon terminals. However, many fine stained axons coursed in all directions within the hilus. In CA3, CA2, and CA1 the pattern of immunoreactivity was similar to Fig. 4 a, b Photomicrographs of a portion of the dentate granule cell layer (GC) and IML in a MaTLE and MTLE hippocampus, respectively, immunostained for GAT1. Note the dense punctate immunoreactivity around the cell bodies (asterisks) of the granule cell layer. In b such intense staining around cell bodies is absent, and instead the immunoreactive puncta appear to extend along the granule cell dendrites into the IML (arrows). c A patch of immunoreactive axons (arrows) in the alveus of a MaTLE hippocampus. d Immunoreactivity along the axon initial segments of pyramidal neurons in area CA2 of the MaTLE hippocampus. This pattern is the same in MTLE hippocampi. Scale bar =100 lm a-d that described for MaTLE except that it reflected the degree of cell loss in these regions (Fig. 5f ). In the CA1 region, while immunoreactivity was reduced within the pyramidal layer due to varying degrees of neuronal loss, a denser network of immunoreactive fibers appeared in the stratum oriens of CA1 ( Fig. 5f compared to 5e ).
Within the subiculum, which in MTLE retains most of its neurons, GAT-1 immunoreactivity appeared throughout the region as fine punctate particles and also along the axon initial segments of pyramidal neurons. Immunoreactivity consistent with axon initial segment labeling was prominent in clusters of layer 2 neurons in the subiculum (Figs. 4d and 5h ) as seen also in MaTLE.
In the alveus there were fewer immunostained axons in MTLE compared to MaTLE. In the MTLE/DYN -group overall the pattern of GAT-1 immunoreactivity was as in MTLE. However, in the molecular layer despite the presence of immunoreactive fibers within it, the IML still retained its clear boundaries and was not completely obliterated as in MTLE.
GAT-1 immunoreactivity in the CA1-only group was clearly reduced in the area CA1, consistent with neuronal loss within this area, the pattern of labeling within the dentate gyrus resembled that of MaTLE except that the immunoreactivity around granular cells did not adhere to the soma as prominently as in Ma-TLE. The IML was more lightly stained than the OML and retained clear borders. Immunostained fibers were seen in the alveus including occasional small neurons in the alveus that were encrusted with immunoreactive processes.
Localization of GAT-3
Non-sclerotic hippocampi-MaTLE and PTLE groups
In general, there was less GAT-3 immunoreactivity in the MaTLE group in which the mass lesion was located outside the hippocampus compared to MTLE. Very faint immunoreactivity was observed in some astrocytes in the subiculum (2/5 cases). No immunoreactivity was seen in the granule cell layer, dentate molecular layer, or the hilus. In the PTLE, immunostaining was similar to that in MaTLE with a very few immunoreactive astrocytes in the hilus (1/3 cases). Fig. 5 a, c, e, g are photomicrographs from a non-sclerotic  hippocampus, b, d , f, h are from a sclerotic hippocampus. a, b are photomicrographs of GAT1 immunoreactivity in the dentate granule cell layer from a non-sclerotic (MaTLE) and sclerotic (MTLE) hippocampus, respectively. Note the loss of labeling around the granule cell bodies (asterisks) in b with dense labeling wrapped around occasional granular neurons (arrowhead). c, d
show portions of the inner molecular layer (IML). In c, the nonsclerotic hippocampus (MaTLE), the GAT1 immunoreactive elements appear as fine dark granular apparently randomly dispersed in all directions, whereas in the sclerotic (MTLE) hippocampus immunoreactivity is reduced but extends vertically along the granule cell dendrites (arrowheads). e, f are the stratum oriens with portions of the pyramidal layer in the non-sclerotic (MaTLE) and sclerotic (MTLE) hippocampus, respectively. Note the dense band of labeling in the stratum oriens in f (arrows). g, h show GAT1 immunoreactivity on the initial axon segments of neurons in layer 2 island of neurons (arrows) in the subiculum of the non-sclerotic and sclerotic hippocampi, respectively. Alv alveus, GC dentate granule cell layer, IML inner molecular layer of dentate, or stratum oriens. The scale bar in a-d =50 lm; E-H =100 lm b Fig. 6 Photomicrographs of GAT3 immunoreactivity. a The dentate gyrus and hilus of an MTLE (sclerotic) hippocampus. Note the immunoreactive astrocytes (arrow) in the IML inner molecular layer, GC granule cell layer, and H hilus. Scale bar =400 lm. b Photomicrograph at higher magnification to show the morphology of the immunoreactive astrocytes. c GAT-3 immunoreactive astrocytes (arrow) on the stratum oriens/alveus border from a patient with a ganglioglioma in the amygdala. d, e Immunoreactive astrocytes in the subcortical white matter from the same patient as in c. Scale bar b, c, e =50 lm; d =100 lm A unique pattern of immunoreactivity was observed in the hippocampus of the patient (IH428) in whom a mass lesion (ganglioglioma) was located in the amygdala. In this case protoplasmic astrocytes were strongly stained in the hilus, granular cell layer, and dentate molecular layer. In addition many clumps of intensely immunoreactive protoplasmic astrocytes were located on the pyramidal cell/alvear border (Fig. 6c) , within the alveus and in the subcortical white matter of the angular bundle (Fig. 6d, e) .
Sclerotic hippocampi-MTLE, MTLE/DYN -, and CA1 only groups
In the MTLE, in contrast to the non-sclerotic hippocampi, there were prominently stained highly branched stellate cells resembling protoplasmic astrocytes (Fig. 6a, b) localized in the dentate granule cell layer (13/ 13 cases), dentate molecular layer (9/13 cases), the subgranular zone and the hilus (13/13 cases) (Fig. 6a) . Generally there were fewer cells in the subgranular zone compared to the deep hilus (Fig. 6a) . Occasionally, a few small neurons and dendrites in the hilus were outlined by punctate immunoreactive elements. Such cells were also seen in the pyramidal layer of CA3 and regions of CA1 where neurons were spared, as well as in the subiculum. In the latter two areas the cells were only lightly stained. GAT-3 immunoreactivity was absent in the sclerotic regions of the hippocampus.
In the MTLE/DYN -hippocampi too, many immunoreactive astrocytes were found in the hilus, granule cell layer, and molecular layer of the dentate (2/2 cases). In the hippocampi with neuronal loss confined to the CA1 region but not the dentate gyrus (CA1 only group), one patient had a pattern of immunoreactivity resembling that of MaTLE with no stained cells in the hilus, whereas in the other there were stained astrocytes in the hilus and the subicular area.
Western blot analysis
To estimate the amount of GAT1 quantitatively, Western blotting was done on whole hippocampal sections from PTLE (n=6) and MTLE (n=9) hippocampi. The Western blots for individual sclerotic (MTLE) and nonsclerotic patients showed that the immunostaining of the bands in the two groups appeared similar (Fig. 7) . The intensity of the blots when quantified and expressed as a percentage of non-sclerotic mean showed no difference between the groups (p=0.82, Mann-Whitney U-test, two tailed) (Fig. 8) . Western blot analysis for GAT3 on whole hippocampal sections showed a main strongly immunoreactive band at the expected molecular mass of 71 kDa, and this band showed no difference between the sclerotic and non-sclerotic groups (Fig. 9, 10 ). However, there was visible difference in band intensities for individual patients across groups. Two very weak bands were also revealed around 50 and 110-120 kDa, but these bands were not apparent in all patients.
Since there are histological differences between the sclerotic and non-sclerotic hippocampi, the former showing a greater loss of neurons (mean percent cell loss 65.08±10.72 SD) compared to the latter (mean 42.0±14% SD) the Western blot optical density levels for GAT1 and GAT3 for each patient were normalized by the percent of neurons remaining. Even with such normalization there was no difference in GAT1 and GAT3 levels between sclerotic and non-sclerotic hippocampi (GAT1: p=0.29, GAT3: p=0.35, Mann-Whitney U, two tail). This similarity suggests that there may be compensatory changes in the sclerotic group. Immunohistochemical data suggest where such changes may occur. In the case of GAT1, though there is cell loss in Fig. 7 Immunoblot (Western blot) of crude SDS extract from human hippocampi subjected to SDS-PAGE (14 lg protein/lane) and reacted with GAT1 antibodies (anti-GABA-Tp(1), rabbit 68514, 6/21/98, 1 lg/ml) followed by peroxidase conjugated secondary antibodies. Each blot consisted of three samples from each patient. There was no significant difference between non-HS (lanes [10] [11] [12] [13] [14] [15] and HS (lanes 1-9) patients. Molecular mass markers are indicated (kDa) Fig. 8 Quantification of Western blots for GAT1 and GAT3 in non-HS (n=6) and HS (n=9) hippocampi. The standard bar plot shows the relative amounts of GAT1 and GAT3 (expressed as percentage of the non-HS mean) quantified from the western blots (see Methods for details). No significant differences in GAT1 or GAT3 between the non-HS and HS groups were detected (GAT1: p=0.82, GAT3: p=0.81, Mann-Whitney U, two-tailed test). The figure also shows that while there is a significant decrease in neurons in the HS hippocampi (* p<0.05) the OD Optical density values normalized by neuron numbers shows no significant difference for GAT1 or GAT3 area CA1, the intensity of staining appears stronger on the neurons remaining in the stratum oriens, and in the molecular layer of the dentate gyrus along granule cell apical dendrites. In the case of GAT3 there is a distinct population of immunoreactive astrocytes most noticeable in the dentate area.
Discussion
The hypothesis evaluated in this study is whether there is a reduction in GABA transporters in the sclerotic (MTLE) hippocampus compared to non-sclerotic hippocampi (MaTLE and PTLE) in patients with medically intractable TLE. The sclerotic rather than the nonsclerotic hippocampus is thought to be epileptogenic [14, 31] . Western blot analysis showed no significant difference in GAT1 levels between the two groups. However, immunohistochemical staining showed regional differences in GAT1 immunoreactivity within the hippocampus. In sclerotic hippocampi there was a loss of staining in sclerotic regions (CA1, CA3, and hilus) but increased staining intensity in regions where neurons survive, such as the granule cell layer and stratum oriens. Taken together with Western blot data this may reflect a compensatory up regulation, and account for the lack of the difference between sclerotic and non-sclerotic hippocampi in the immunoblots. It is also noteworthy that GABAergic neurons, which we argue are the source of GAT1 transporter, survive in the sclerotic hippocampus [2] . These observations are not surprising as an increase in GAT1 expression is reported in some animal models of epilepsy while a down regulation is seen in others (reviewed in [8] ). Likewise compensatory changes in GAT3 may be due to an increased population of GAT3 immunoreactive astrocytes in the dentate and hilar regions and GAT3 reactive elements surrounding some surviving neurons in other regions (CA3, CA1, and subiculum). It may be inferred from this data that rather than an overall decrease in GABA transporters, there is at best no overall change.
The significance of these expression patterns must be interpreted in the context of whether they are primary modifications responsible for the causation and maintenance of seizures or whether they are secondary adaptive changes. Intrahippocampal regional changes in expression patterns shed some light on these questions.
Distribution of GABA transporters
The distribution of GABA transporters in the human hippocampus has been described only in two other studies [1, 32] . The patterns for GAT1 described in the non-sclerotic hippocampi and autopsy controls are similar to that described for our non-sclerotic patients, and may thus be considered the ''normal'' pattern. Likewise the patterns in the sclerotic hippocampi [1, 32] correspond to those of our sclerotic (MTLE) group, showing loss of immunoreactivity in the dentate gyrus Fig. 10 Photomicrographs of the dentate granule cell layer in nonsclerotic hippocampi (MaTLE) immunostained for GABA (a) and GAT1 (b). The immunoreactive terminals are seen as fine black grain-like particles, and show a similar pattern of innervation of the granular neurons (asterisk). Bar =50 lm Fig. 9 Western blots of representative non-MTLE and MTLE patient hippocampi (20 lg protein/lane) immunostained with antibodies against GAT3 reveal strong single bands around the expected molecular mass of 71 kDa. There was no significant difference in GAT3 protein between the non-MTLE and MTLE hippocampi. Two very weak single bands are also seen around 50 and 110-120 kDa, respectively. These bands were not apparent in all patients. Molecular mass markers are indicated (kDa) and hippocampal formation but not in the subiculum. No western blot quantitation was done in either of these previous studies.
Ultrastructural studies in the monkey and human have revealed that GAT-1 is localized in presynaptic terminals [1, 16] . The neurons carrying these transporters are GABAergic [34] . In the human hippocampus the pattern of GABAergic distribution resembles closely that of GAT1. This is shown for the dentate granule cell layer in Fig. 10 . Thus, the role of GAT-1 in the human hippocampus appears to be the uptake of GABA released synaptically by GABAergic neurons. The most prominent alteration in GAT-1 localization was seen in the dentate gyrus. In the non-sclerotic (MaTLE and PTLE) hippocampi, GAT1-containing axons and terminals were distributed in high density around the granule cell somata. The presence of GAT-1 containing putative GABAergic terminals on the cell body suggests a very powerful and efficient inhibitory mechanism of granule cell excitation. In MTLE, with the loss of a substantial number of granule cells, the GAT-1 immunoreactivity in most areas of the granule cell layer is less dense around the cell body, and additionally, shows a new pattern of distribution along the entire length of surviving granule cell apical dendrites (including an increase in the IML). The lower density of putative GABAergic terminals on the granule cell bodies may explain the reduced inhibition of the granule cells, resulting in increased excitability of these cells [30, 39] , and also the prolonged GABA response [40] . Electrophysiological studies have indeed shown that in the dentate gyrus of the MTLE hippocampus the GABA transporter system is functionally compromised in both the forward and reverse direction [33] . The presence of new GAT-1 expressing (and presumably GABA releasing) terminals along the granule cell dendrites may ameliorate some of the loss of inhibition at the cell body and thus account for the reports of only a small reduction of GABA mediated inhibition in these neurons [30] . Similar mechanisms are reported in kindled rats, where it is shown that GAT-1 immunoreactivity is reduced on dentate granule cell bodies and axon initial segments coincident with the loss of inhibition and emergence of spontaneous seizures [35] .
The patterns of GAT-3 expression described in the study by Mathern et al. [32] differ from those reported here. They report that the GAT-3 labeled astrocytes, similar to the ones we described, were greater in number in the non-sclerotic hippocampi compared to the sclerotic ones. Our observations suggest the opposite. In fact, we observed GAT-3 labeled protoplasmic astrocytes in only one unusual tumor-case, where the tumor was located in the amygdala closely abutting the hippocampus. None of the other MaTLE (with mass lesions located extrahipocampally) or PTLE patients had such immunoreactive GAT-3 astrocytes. Though the two studies use antibodies from different sources, this may not be a significant issue for the differences. Our finding of very little GAT-3 in the non-sclerotic hippocampi is wholly consistent with animal localization studies using immunohistochemistry and in situ hybridization [19, 22] .
The presence of GAT-3 positive large protoplasmic astrocytes in the hippocampi from MTLE patients represents a distinctive disease-related feature and not due to other factors such as AEDs at the time of surgery. Their expression may be related to the degree of hyperexcitability of the hippocampus [14, 15] . The degree of hyperexcitability of dentate granule cells has been assessed by the ''excitability index'' by Williamson et al. [40] . This index is the sum of four electrophysiological variables obtained from intracellular recordings-the ability to evoke multiple actions potentials (bursts) with dentate molecular layer stimulation; the presence or absence of evoked inhibitory postsynaptic potentials; the absence and presence of presumed polysynaptic events on the falling phase of the evoked response and spontaneous baseline excitatory activity. Thus, labeled, large protoplasmic astrocytes are most prominent in the MTLE, MTLE/DYN -, and the CA1 only group, which are the groups with the greatest excitability index [14, 15] . They are fewer in PTLE, which has a lower excitability index, and least in MaTLE with normal excitability [14] . The excitability index for the MaTLE patient IH428, which had GAT3 positive astrocytes, is not available, but it is significant that this patient showed a pattern of cell loss resembling sclerosis, as did the MTLE.
Thus while GAT 1 reductions may cause regional increases in the excitability of neurons, e.g. dentate granule cells, because of the loss of inhibition normally associated with GABA release from GAT1 bearing terminals, the increase in GAT3 astrocytes in patient groups may contribute to the excitable state by excess removal of GABA.
